Chimeric antigen receptor (CAR) T-cell persistence at month 3 predicts clinical outcomes in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with obecabtagene autoleucel (obe-cel)
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Claire Roddie, Jae Park, Eleni Tholouli, Karamjeet Sandhu, Paul Shaughnessy, Pere Barba, Manuel Guerreiro, Deborah Yallop, Aaron Logan, Mehrdad Abedi, Pierre Lao-Sirieix, Ping Wang, Wolfram Brugger, Bijal Shah, Anthony Hunter, Daniel Deangelo, Elias Jabbour
Institutions: University College London, Memorial Sloan Kettering Cancer Center, Manchester Royal Infirmary, City Of Hope National Medical Center, Methodist Healthcare, Universitat Autònoma de Barcelona, Vall d'Hebron Hospital Universitari, Hospital Universitari i Politècnic La Fe, King's College Hospital NHS Foundation Trust, King's College Hospital, University of California, San Francisco, University of California, Davis, Autolus (United Kingdom), Moffitt Cancer Center, University of Chicago, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7108711348